Gabapentin
Product Images NDC 68071-2907

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68071-2907). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2907 1)

Label for Gabapentin 300 mg capsules from NuCare Pharmaceuticals, Inc., package contains 100 capsules. The label includes the NDC number 68071-2907-1, states 'Rx Only,' and directs to see manufacturer's label for ingredients. It also displays storage instructions and warnings.*

FDA Label Image

Equation Of Cockcroft And Gault (Gabapentin Fig1)

An illustration showing the formula to calculate creatinine clearance (CLCr) based on age, weight, serum creatinine level, and sex, which is the Cockcroft-Gault equation used for estimating kidney function.*

FDA Label Image

Fig-2 (Gabapentin Fig2)

A line graph depicting mean pain scores over an 8-week period for placebo and Gabapentin 3600 mg/day groups, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis represents mean pain score from 0 to 10, and the x-axis represents weeks from baseline to 8.*

FDA Label Image

Fig-3 (Gabapentin Fig3)

A line graph depicting mean pain scores over a 7-week period comparing placebo with two doses of Gabapentin (1800 mg/day and 2400 mg/day). The x-axis represents weeks from baseline to week 7, and the y-axis shows mean pain scores from 0 to 10. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)

A bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing data from two studies. It compares placebo (PBO) to gabapentin (GBP) at dosages 1800 mg, 2400 mg, and 3600 mg. The graph depicts higher response rates for gabapentin groups, with percentages and significance indicated.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

A scatter plot comparing percentage difference versus daily dose in milligrams (600, 900, 1200, 1800 mg) for three labeled groups: STUDY a, STUDY b, and STUDY c. Data points for each study are marked distinctly with legends identifying the studies.*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure diagram of Gabapentin showing a cyclohexane ring bonded to an amino group (CH2NH2) and a carboxyl group (CH2CO2H).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.